Seasonal influenza vaccine performance and the potential benefits of mRNA vaccines

References

• Yamayoshi S, Kawaoka Y. Current and future influenza vaccines. Nat Med. 2019 Feb;25(2):212–13. doi:10.1038/s41591-018-0340-z.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Vaccines against influenza: WHO position paper - May 2022. Weekly Epidemiological Record. 2022;19(97):185–208.
   Google Scholar
• Paget J, Staadegaard L, Wang X, Li Y, van Pomeren T, van Summeren J, Dückers M, Chaves SS, Johnson EK, Mahé C, et al. Global and national influenza-associated hospitalisation rates: estimates for 40 countries and administrative regions. J Glob Health. 2023 Jan 27;13:04003. doi:10.7189/jogh.13.04003.
   PubMed Web of Science ®Google Scholar
• Iuliano AD, Roguski KM, Chang HH, Muscatello DJ, Palekar R, Tempia S, Cohen C, Gran JM, Schanzer D, Cowling BJ, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2018 Mar 31;391(10127):1285–300. doi:10.1016/s0140-6736(17)33293-2.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Estimated flu-related illnesses, medical visits, hospitalizations, and deaths in the United States — 2019–2020 flu season. Vol. 2022. 2022 Oct 7. https://www.cdc.gov/flu/about/burden/2019-2020.html.
   Google Scholar
• Krammer F, Smith GJD, Fouchier RAM, Peiris M, Kedzierska K, Doherty PC, Palese P, Shaw ML, Treanor J, Webster RG, et al. Influenza. Nat Rev Dis Primers. 2018 Jun 28;4(1):3. doi:10.1038/s41572-018-0002-y.
   PubMedGoogle Scholar
• Koutsakos M, Wheatley AK, Laurie K, Kent SJ, Rockman S. Influenza lineage extinction during the COVID-19 pandemic? Nat Rev Microbiol. 2021 Dec;19(12):741–2. doi:10.1038/s41579-021-00642-4.
   PubMed Web of Science ®Google Scholar
• Paget J, Caini S, Del Riccio M, van Waarden W, Meijer A. Has influenza B/Yamagata become extinct and what implications might this have for quadrivalent influenza vaccines? Euro Surveill. 2022 Sep;27(39). doi:10.2807/1560.7917.Es.2022.27.39.2200753.
   PubMedGoogle Scholar
• Hansen CL, Chaves SS, Demont C, Viboud C. Mortality associated with influenza and respiratory syncytial virus in the US, 1999-2018. JAMA Netw Open. 2022 Feb 1;5(2):e220527. doi:10.1001/jamanetworkopen.2022.0527.
   PubMed Web of Science ®Google Scholar
• Matias G, Taylor R, Haguinet F, Schuck-Paim C, Lustig R, Shinde V. Estimates of hospitalization attributable to influenza and RSV in the US during 1997-2009, by age and risk status. BMC Public Health. 2017 Mar 21;17(1):271. doi:10.1186/s12889-017-4177-z.
   PubMedGoogle Scholar
• Barr IG, Donis RO, Katz JM, McCauley JW, Odagiri T, Trusheim H, Tsai TF, Wentworth DE. Cell culture-derived influenza vaccines in the severe 2017–2018 epidemic season: a step towards improved influenza vaccine effectiveness. NPJ Vaccines. 2018;3:44. doi:10.1038/s41541-018-0079-z.
   PubMed Web of Science ®Google Scholar
• Belongia EA, Simpson MD, King JP, Sundaram ME, Kelley NS, Osterholm MT, McLean HQ. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis. 2016 Aug;16(8):942–51. doi:10.1016/s1473-3099(16)00129-8.
   PubMed Web of Science ®Google Scholar
• Belongia EA, McLean HQ. Influenza vaccine effectiveness: defining the H3N2 problem. Clin Infect Dis. 2019 Oct 30;69(10):1817–23. doi:10.1093/cid/ciz411.
   PubMed Web of Science ®Google Scholar
• Neher RA, Bedford T, Daniels RS, Russell CA, Shraiman BI. Prediction, dynamics, and visualization of antigenic phenotypes of seasonal influenza viruses. Proc Natl Acad Sci. 2016;113(12):1701–9. doi:10.1073/pnas.1525578113.
   Web of Science ®Google Scholar
• Rajaram S, Boikos C, Gelone DK, Gandhi A. Influenza vaccines: the potential benefits of cell-culture isolation and manufacturing. Ther Adv Vaccines Immunother. 2020;8:2515135520908121. doi:10.1177/2515135520908121.
   Google Scholar
• Zost SJ, Parkhouse K, Gumina ME, Kim K, Diaz Perez S, Wilson PC, Treanor JJ, Sant AJ, Cobey S, Hensley SE, et al. Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. Proc Natl Acad Sci U S A. 2017 Nov 21;114(47):12578–83. doi:10.1073/pnas.1712377114.
   PubMed Web of Science ®Google Scholar
• Sanyal M, Holmes TH, Maecker HT Albrecht RA, Dekker CL, He XS, Greenberg HB. Diminished B-Cell response after repeat influenza vaccination. J Infect Dis. 2019 Apr 19;219(10):1586–95. doi:10.1093/infdis/jiy685.
   PubMed Web of Science ®Google Scholar
• Jones-Gray E, Robinson EJ, Kucharski AJ, Fox A, Sullivan SG. Does repeated influenza vaccination attenuate effectiveness? A systematic review and meta-analysis. Lancet Respir Med. 2023 Jan;11(1):27–44. doi:10.1016/s2213-2600(22)00266-1.
   PubMed Web of Science ®Google Scholar
• McElhaney JE, Verschoor CP, Andrew MK, Haynes L, Kuchel GA, Pawelec G. The immune response to influenza in older humans: beyond immune senescence. Immun Ageing. 2020;17(1):10. doi:10.1186/s12979-020-00181-1.
   PubMed Web of Science ®Google Scholar
• Hughes K, Middleton DB, Nowalk MP, Balasubramani GK, Martin ET, Gaglani M, Talbot HK, Patel MM, Ferdinands JM, Zimmerman RK, et al. Effectiveness of influenza vaccine for preventing laboratory-confirmed influenza hospitalizations in immunocompromised adults. Clin Infect Dis. 2021 Dec 6;73(11):4353–60. doi:10.1093/cid/ciaa1927.
   Web of Science ®Google Scholar
• Gärtner BC, Weinke T, Wahle K, Kwetkat A, Beier D, Schmidt KJ, Schwarz TF. Importance and value of adjuvanted influenza vaccine in the care of older adults from a European perspective – a systematic review of recently published literature on real-world data. Vaccine. 2022 May 11;40(22):2999–3008. doi:10.1016/j.vaccine.2022.04.019.
   PubMed Web of Science ®Google Scholar
• Lee JKH, Lam GKL, Shin T, Samson SI, Greenberg DP, Chit A. Efficacy and effectiveness of high-dose influenza vaccine in older adults by circulating strain and antigenic match: an updated systematic review and meta-analysis. Vaccine. 2021 Mar 15;39(Suppl 1):A24–35. doi:10.1016/j.vaccine.2020.09.004.
   PubMedGoogle Scholar
• Li APY, Cohen CA, Leung NHL, Fang VJ, Gangappa S, Sambhara S, Levine MZ, Iuliano AD, Perera RAPM, Ip DKM, et al. Immunogenicity of standard, high-dose, MF59-adjuvanted, and recombinant-HA seasonal influenza vaccination in older adults. NPJ Vaccines. 2021 Feb 16;6(1):25. doi:10.1038/s41541-021-00289-5.
   PubMed Web of Science ®Google Scholar
• Gebre MS, Brito LA, Tostanoski LH, Edwards DK, Carfi A, Barouch DH. Novel approaches for vaccine development. Cell. 2021 Mar 18;184(6):1589–603. doi:10.1016/j.cell.2021.02.030.
   PubMed Web of Science ®Google Scholar
• Sahin U, Karikó K, Ö T. mRNA-based therapeutics — developing a new class of drugs. Nat Rev Drug Discov. 2014 Oct 1;13(10):759–80. doi:10.1038/nrd4278.
   PubMed Web of Science ®Google Scholar
• Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov. 2018 Apr;17(4):261–79. doi:10.1038/nrd.2017.243.
   PubMed Web of Science ®Google Scholar
• Skowronski DM, Janjua NZ, Sabaiduc S, De Serres G, Winter A-L, Gubbay JB, Dickinson JA, Fonseca K, Charest H, Bastien N, et al. Influenza A/Subtype and B/Lineage effectiveness estimates for the 2011–2012 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine. J Infect Dis. 2014 Jul 1;210(1):126–37. doi:10.1093/infdis/jiu048.
   PubMed Web of Science ®Google Scholar
• Chambers BS, Parkhouse K, Ross TM, Alby K, Hensley SE. Identification of hemagglutinin residues responsible for H3N2 antigenic drift during the 2014-2015 influenza season. Cell Rep. 2015 Jul 7;12(1):1–6. doi:10.1016/j.celrep.2015.06.005.
   PubMed Web of Science ®Google Scholar
• Flannery B, Zimmerman RK, Gubareva LV, Garten RJ, Chung JR, Nowalk MP, Jackson ML, Jackson LA, Monto AS, Ohmit SE, et al. Enhanced genetic characterization of influenza A(H3N2) viruses and vaccine effectiveness by genetic group, 2014–2015. J Infect Dis. 2016 Oct 1;214(7):1010–19. doi:10.1093/infdis/jiw181.
   PubMed Web of Science ®Google Scholar
• Flannery B, Kondor RJG, Chung JR, Gaglani M, Reis M, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Monto AS, et al. Spread of antigenically drifted influenza A(H3N2) viruses and vaccine effectiveness in the United States during the 2018–2019 season. J Infect Dis . 2020 Jan 1;221(1):8–15. doi:10.1093/infdis/jiz543.
   PubMed Web of Science ®Google Scholar
• Tenforde MW, Kondor RJG, Chung JR, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Monto AS, Martin ET, Belongia EA, et al. Effect of antigenic drift on influenza vaccine effectiveness in the United States—2019–2020. Clin Infect Dis. 2021 Dec 6;73(11):4244–50. doi:10.1093/cid/ciaa1884.
   Web of Science ®Google Scholar
• World Health Organization. Recommended composition of influenza virus vaccines for use in the 2019–2020 northern hemisphere influenza season. Meeting report. 2019 Feb 21. https://cdn.who.int/media/docs/default-source/influenza/who-influenza-recommendations/vcm-northern-hemisphere-recommendation-2019-2020/201902-recommendation.pdf?sfvrsn=7aa5b685_13
   Google Scholar
• World Health Organization. Recommended composition of influenza virus vaccines for use in the 2013–2014 northern hemisphere influenza season. Wkly Epidemiol Rec. 2013 Mar 8;88(10):101–14.
   PubMedGoogle Scholar
• World Health Organization. Recommended composition of influenza virus vaccines for use in the 2016–2017 northern hemisphere influenza season. Wkly Epidemiol Rec. 2016 Mar 11;91(10):121–32.
   PubMedGoogle Scholar
• World Health Organization. Recommended composition of influenza virus vaccines for use in the 2017–2018 northern hemisphere influenza season. Wkly Epidemiol Rec. 2017 Mar 17;92(11):117–28.
   PubMedGoogle Scholar
• World Health Organization. Addendum to the recommended composition of influenza virus vaccines for use in the 2019–2020 northern hemisphere influenza season. 2019. https://cdn.who.int/media/docs/default-source/influenza/who-influenza-recommendations/vcm-northern-hemisphere-recommendation-2019-2020/201902-recommendation-addendum.pdf?sfvrsn=cb164a4b_13
   Google Scholar
• World Health Organization. Recommended composition of influenza virus vaccines for use in the 2011–2012 northern hemisphere influenza season. Wkly Epidemiol Rec. 2011 Mar 4;86(10):86–90.
   PubMedGoogle Scholar
• World Health Organization. Recommended composition of influenza virus vaccines for use in the 2012–2013 northern hemisphere influenza season. Wkly Epidemiol Rec. 2012 Mar 9;87(10):83–95.
   PubMedGoogle Scholar
• World Health Organization. Recommended composition of influenza virus vaccines for use in the 2014–2015 northern hemisphere influenza season. Wkly Epidemiol Rec. Mar 7 2014;89(10):93–104.
   PubMedGoogle Scholar
• World Health Organization. Recommended composition of influenza virus vaccines for use in the 2015–2016 northern hemisphere influenza season. Wkly Epidemiol Rec. 2015 Mar 13;90(11):97–108.
   PubMedGoogle Scholar
• World Health Organization. Recommended composition of influenza virus vaccines for use in the 2018–2019 northern hemisphere influenza season. Wkly Epidemiol Rec. 2018 Mar 23;93(12):133–41.
   PubMedGoogle Scholar
• Skowronski DM, Janjua NZ, De Serres G, Sabaiduc S, Eshaghi A, Dickinson JA, Fonseca K, Winter A-L, Gubbay JB, Krajden M, et al. Low 2012–13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. PLoS One. 2014;9(3):e92153. doi:10.1371/journal.pone.0092153.
   PubMed Web of Science ®Google Scholar
• Garretson TA, Petrie JG, Martin ET, Monto AS, Hensley SE. Identification of human vaccines that possess antibodies targeting the egg-adapted hemagglutinin receptor binding site of an H1N1 influenza vaccine strain. Vaccine. 2018 Jun 27;36(28):4095–101. doi:10.1016/j.vaccine.2018.05.086.
   PubMed Web of Science ®Google Scholar
• Wu NC, Zost SJ, Thompson AJ, Oyen D, Nycholat CM, McBride R, Paulson JC, Hensley SE, Wilson IA. A structural explanation for the low effectiveness of the seasonal influenza H3N2 vaccine. PLoS Pathog. 2017 Oct;13(10):e1006682. doi:10.1371/journal.ppat.1006682.
   PubMed Web of Science ®Google Scholar
• Kissling E, Pozo F, Buda S, Vilcu A-M, Rizzo C, Gherasim A, Horváth JK, Brytting M, Domegan L, Meijer A, et al. Effectiveness of influenza vaccine against influenza A in Europe in seasons of different A(H1N1)pdm09 and the same A(H3N2) vaccine components (2016–17 and 2017–18). Vaccine X. 2019 Dec 10;3:100042. doi:10.1016/j.jvacx.2019.100042.
   PubMedGoogle Scholar
• Levine MZ, Martin ET, Petrie JG, Lauring AS, Holiday C, Jefferson S, Fitzsimmons WJ, Johnson E, Ferdinands JM, Monto AS. Antibodies against egg- and cell-grown influenza A(H3N2) viruses in adults hospitalized during the 2017–2018 influenza season. J Infect Dis. 2019 May 24;219(12):1904–12. doi:10.1093/infdis/jiz049.
   PubMed Web of Science ®Google Scholar
• Liu F, Gross FL, Jefferson SN, Holiday C, Bai Y, Wang L, Zhou B, Levine MZ. Age-specific effects of vaccine egg adaptation and immune priming on A(H3N2) antibody responses following influenza vaccination. J Clin Invest. 2021 Apr 15;131(8). doi:10.1172/jci146138.
   Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Past seasons vaccine effectiveness estimates. [accessed 2022 Jun 9]. https://www.cdc.gov/flu/vaccines-work/past-seasons-estimates.html.
   Google Scholar
• Network CISPS. Canadian sentinel practitioner surveillance network (SPSN) influenza vaccine effectiveness estimates % (95% CI), 2004-05 to 2021-22 seasons. [accessed 2022 Oct 31]. http://www.bccdc.ca/resource-gallery/Documents/Statistics%20and%20Research/Publications/Epid/Influenza%20and%20Respiratory/SPSN_VE_By_Year_Table.pdf
   Google Scholar
• Kissling E, Valenciano M, Larrauri A, Oroszi B, Cohen JM, Nunes B, Pitigoi D, Rizzo C, Rebolledo J, Paradowska-Stankiewicz I, et al. Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case–control study. Euro Surveill. 2013 Jan 31;18(5). doi:10.2807/ese.18.05.20390-en
   Google Scholar
• Kissling E, Valenciano M, Buchholz U, Larrauri A, Cohen JM, Nunes B, Rogalska J, Pitigoi D, Paradowska-Stankiewicz I, Reuss A, et al. Influenza vaccine effectiveness estimates in Europe in a season with three influenza type/subtypes circulating: the I-MOVE multicentre case–control study, influenza season 2012/13. Euro Surveill. 2014 Feb 13;19(6). doi:10.2807/1560-7917.es2014.19.6.20701.
   PubMedGoogle Scholar
• Valenciano M, Kissling E, Reuss A, Jiménez-Jorge S, Horváth JK, Donnell JMO, Pitigoi D, Machado A, Pozo F. The European I-MOVE multicentre 2013–2014 case-control study. Homogeneous moderate influenza vaccine effectiveness against A(H1N1)pdm09 and heterogenous results by country against A(H3N2). Vaccine. 2015 Jun 4;33(24):2813–22. doi:10.1016/j.vaccine.2015.04.012.
   PubMed Web of Science ®Google Scholar
• Valenciano M, Kissling E, Reuss A, Rizzo C, Gherasim A, Horváth JK, Domegan L, Pitigoi D, Machado A, Paradowska-Stankiewicz IA, et al. Vaccine effectiveness in preventing laboratory-confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE multicentre case–control study, Europe 2014/15. Euro Surveill. 2016;21(7):ii=30139. doi:10.2807/1560-7917.Es.2016.21.7.30139.
   Google Scholar
• Kissling E, Valenciano M, Pozo F, Vilcu A-M, Reuss A, Rizzo C, Larrauri A, Horváth JK, Brytting M, Domegan L, et al. 2015/16 I-MOVE/I-MOVE+ multicentre case-control study in Europe: moderate vaccine effectiveness estimates against influenza A(H1N1)pdm09 and low estimates against lineage-mismatched influenza B among children. Influenza Other Respir Viruses. 2018 Jul;12(4):423–37. doi:10.1111/irv.12520.
   PubMed Web of Science ®Google Scholar
• Kissling E, Rondy M. Early 2016/17 vaccine effectiveness estimates against influenza A(H3N2): I-MOVE multicentre case control studies at primary care and hospital levels in Europe. Euro Surveill. 2017 Feb 16;22(7). doi:10.2807/1560-7917.Es.2017.22.7.30464.
   PubMedGoogle Scholar
• Rondy M, Kissling E, Emborg HD, Gherasim A, Pebody R, Trebbien R, Pozo F, Larrauri A, McMenamin J, Valenciano M. Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies. Eurosurveillance. 2018 Mar;23(9). doi:10.2807/1560-7917.Es.2018.23.9.18-00086.
   Web of Science ®Google Scholar
• Kissling E, Rose A, Emborg HD, Gherasim A, Pebody R, Pozo F, Trebbien R, Mazagatos C, Whitaker H, Valenciano M. Interim 2018/19 influenza vaccine effectiveness: six European studies, October 2018 to January 2019. Eurosurveillance. 2019 Feb;24(8). doi:10.2807/1560-7917.Es.2019.24.1900121.
   Web of Science ®Google Scholar
• Rose A, Kissling E, Emborg HD, Larrauri A, McMenamin J, Pozo F, Trebbien R, Mazagatos C, Whitaker H, Valenciano M. Interim 2019/20 influenza vaccine effectiveness: six European studies, September 2019 to January 2020. Eurosurveillance. 2020 Mar;25(10). doi:10.2807/1560-7917.Es.2020.25.10.2000153.
   Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Update: influenza activity - United States, 2011-12 season and composition of the 2012-13 influenza vaccine. MMWR Morb Mortal Wkly Rep. 2012 Jun 8;61(22):414–20.
   PubMedGoogle Scholar
• Appiah GD, Blanton L, D’Mello T, Kniss K, Smith S, Mustaquim D, Steffens C, Dhara R, Cohen J, Chaves SS, et al. Influenza activity - United States, 2014–15 season and composition of the 2015-16 influenza vaccine. MMWR Morb Mortal Wkly Rep. 2015 Jun 5;64(21):583–90.
   PubMed Web of Science ®Google Scholar
• Xu X, Blanton L, Elal AIA, Alabi N, Barnes J, Biggerstaff M, Brammer L, Budd AP, Burns E, Cummings CN, et al. Update: influenza activity in the United States during the 2018–19 season and composition of the 2019–20 influenza vaccine. MMWR Morb Mortal Wkly Rep. 2019 Jun 21;68(24):544–51. doi:10.15585/mmwr.mm6824a3.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. U.S. Influenza surveillance report (FluView): week 14. centers for disease control and prevention. [accessed 2022 Dec]. https://www.cdc.gov/flu/weekly/weeklyarchives2019-2020/Week14.htm
   Google Scholar
• Centers for Disease Control and Prevention. Influenza activity–United States, 2012-13 season and composition of the 2013–14 influenza vaccine. MMWR Morb Mortal Wkly Rep. Jun 14 2013;62(23):473–9.
   PubMed Web of Science ®Google Scholar
• Davlin SL, Blanton L, Kniss K, Mustaquim D, Smith S, Kramer N, Cohen J, Cummings CN, Garg S, Flannery B, et al. Influenza activity — United States, 2015–16 season and composition of the 2016–17 influenza vaccine. MMWR Morb Mortal Wkly Rep. 2016 Jun 10;65(22):567–75. doi:10.15585/mmwr.mm6522a3.
   PubMed Web of Science ®Google Scholar
• Blanton L, Alabi N, Mustaquim D, Taylor C, Kniss K, Kramer N, Budd A, Garg S, Cummings CN, Chung J, et al. Update: influenza activity in the United States during the 2016–17 season and composition of the 2017–18 influenza vaccine. MMWR Morb Mortal Wkly Rep. 2017 Jun 30;66(25):668–76. doi:10.15585/mmwr.mm6625a3.
   PubMed Web of Science ®Google Scholar
• Garten R, Blanton L, Elal AIA, Alabi N, Barnes J, Biggerstaff M, Brammer L, Budd AP, Burns E, Cummings CN, et al. Update: influenza activity in the United States during the 2017–18 season and composition of the 2018–19 influenza vaccine. MMWR Morb Mortal Wkly Rep. 2018 Jun 8;67(22):634–42. doi:10.15585/mmwr.mm6722a4.
   PubMed Web of Science ®Google Scholar
• Epperson S, Blanton L, Kniss K, Mustaquim D, Steffens C, Wallis T, Dhara R, Leon M, Perez A, Chaves SS, et al. Influenza activity - United States, 2013-14 season and composition of the 2014-15 influenza vaccines. MMWR Morb Mortal Wkly Rep. 2014 Jun 6;63(22):483–90.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Influenza (flu) antigenic characterization. centers for disease control and prevention. 2022 Dec 2 [accessed 2023 Jan].https://www.cdc.gov/flu/about/professionals/antigenic.htm
   Google Scholar
• Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Winter A-L, Dickinson JA, Gubbay J, Fonseca K, Charest H, Krajden M, et al. Integrated sentinel surveillance linking genetic, antigenic, and epidemiologic monitoring of influenza vaccine-virus relatedness and effectiveness during the 2013–2014 influenza season. J Infect Dis. 2015 Sep 1;212(5):726–39. doi:10.1093/infdis/jiv177.
   PubMed Web of Science ®Google Scholar
• Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Winter A-L, Dickinson JA, Gubbay JB, Drews SJ, Martineau C, Charest H, et al. Beyond antigenic match: possible agent-host and immuno-epidemiological influences on influenza vaccine effectiveness during the 2015–2016 season in Canada. J Infect Dis . 2017 Dec 19;216(12):1487–500. doi:10.1093/infdis/jix526.
   PubMed Web of Science ®Google Scholar
• Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Winter A-L, Dickinson JA, Krajden M, Gubbay JB, Drews SJ, Martineau C, et al. A perfect storm: impact of genomic variation and serial vaccination on low influenza vaccine effectiveness during the 2014–2015 season. Clin Infect Dis. 2016 Jul 1;63(1):21–32. doi:10.1093/cid/ciw176.
   PubMed Web of Science ®Google Scholar
• Skowronski DM, Leir S, Sabaiduc S, Murti M, Dickinson JA, Olsha R, Gubbay JB, Croxen MA, Charest H, Chan T, et al. Interim estimates of 2018/19 vaccine effectiveness against influenza A(H1N1)pdm09 Canada, Jan 2019. Euro Surveill. 2019 Jan;24(4). doi:10.2807/1560-7917.Es.2019.24.4.1900055.
   Google Scholar
• Skowronski DM, Zou M, Sabaiduc S, Murti M, Olsha R, Dickinson JA, Gubbay JB, Croxen MA, Charest H, Jassem A, et al. Interim estimates of 2019/20 vaccine effectiveness during early-season co-circulation of influenza a and B viruses, Canada, February 2020. Eurosurveillance. 2020 Feb;25(7). doi:10.2807/1560-7917.Es.2020.25.7.2000103.
   Web of Science ®Google Scholar
• Skowronski DM, Leir S, Sabaiduc S, Chambers C, Zou M, Rose C, Olsha R, Dickinson JA, Winter A-L, Jassem A, et al. Influenza vaccine effectiveness by A(H3N2) phylogenetic subcluster and prior vaccination history: 2016–2017 and 2017–2018 epidemics in Canada. J Infect Dis. 2022 Apr 19;225(8):1387–98. doi:10.1093/infdis/jiaa138.
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. Surveillance report: communicable diseases - annual epidemiological report [2011 data]. 2013. Reporting on 2011 surveillance data and 2012 epidemic intelligence data. https://www.ecdc.europa.eu/sites/default/files/media/en/publications/Publications/annual-epidemiological-report-2013.pdf
   Google Scholar
• European Centre for Disease Prevention and Control. Surveillance report: respiratory tract infections - annual epidemiological report for 2012-13. 2014. https://www.ecdc.europa.eu/sites/default/files/media/en/publications/Publications/Respiratory-tract-infections-annual-epidemiological-report-2014.pdf
   Google Scholar
• European Centre for Disease Prevention and Control. Surveillance report: seasonal influenza - annual epidemiological report for 2013-14 season. 2014. https://www.ecdc.europa.eu/sites/default/files/media/en/publications/Publications/Influenza-2013-14-season-report.pdf
   Google Scholar
• European Centre for Disease Prevention and Control. Surveillance report: seasonal influenza - annual epidemiological report for 2014-15 season. 2016. https://www.ecdc.europa.eu/en/publications-data/seasonal-influenza-annual-epidemiological-report-2014-15-season
   Google Scholar
• European Centre for Disease Prevention and Control. Surveillance report: seasonal influenza - annual epidemiological report for 2015-16 season. 2017. https://www.ecdc.europa.eu/en/publications-data/seasonal-influenza-annual-epidemiological-report-2015-16-season
   Google Scholar
• European Centre for Disease Prevention and Control. Surveillance report: seasonal influenza - annual epidemiological report for 2016-17 season. 2018. https://www.ecdc.europa.eu/sites/default/files/documents/AER_for_2016-influenza-seasonal.pdf
   Google Scholar
• European Centre for Disease Prevention and Control. Surveillance report: seasonal influenza - annual epidemiological report for 2017-2018 season. 2018. https://www.ecdc.europa.eu/sites/default/files/documents/AER_for_2017-seasonal-influenza.pdf
   Google Scholar
• European Centre for Disease Prevention and Control. Surveillance report: seasonal influenza, annual epidemiological report for 2018–2019 season. 2019. https://www.ecdc.europa.eu/sites/default/files/documents/AER_for_2018_seasonal-influenza-corrected.pdf
   Google Scholar
• European Centre for Disease Prevention and Control. Surveillance report: seasonal influenza - annual epidemiological report for 2019–2020 season. 2020. https://www.ecdc.europa.eu/sites/default/files/documents/AER_for_2019_influenza-seasonal.pdf
   Google Scholar
• Centers for Disease Control and Prevention. Seasonal Influenza Vaccine Effectiveness, 2011-2012. Centers for disease control and prevention. 2018 Sep [accessed 2022 Dec]. https://www.cdc.gov/flu/vaccines-work/2011-2012.html
   Google Scholar
• Centers for Disease Control and Prevention. Seasonal Influenza Vaccine Effectiveness, 2014-2015. Centers for disease control and prevention. 2019 Oct [accessed 2022 Dec]. https://www.cdc.gov/flu/vaccines-work/2014-2015.html
   Google Scholar
• Centers for Disease Control and Prevention. US flu VE data for 2018-2019. Centers for disease control and prevention. 2019 Nov [accessed 2022 Dec]. https://www.cdc.gov/flu/vaccines-work/2018-2019.html
   Google Scholar
• Centers for Disease Control and Prevention. US flu VE data for 2019-2020. Centers for disease control and prevention. 2020 Dec [accessed 2022 Dec]. https://www.cdc.gov/flu/vaccines-work/2019-2020.html
   Google Scholar
• Skowronski DM, Janjua NZ, De Serres G, Winter A-L, Dickinson JA, Gardy JL, Gubbay J, Fonseca K, Charest H, Crowcroft NS, et al. A sentinel platform to evaluate influenza vaccine effectiveness and new variant circulation, Canada 2010–2011 season. Clin Infect Dis. 2012 Aug;55(3):332–42. doi:10.1093/cid/cis431.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Seasonal Influenza Vaccine Effectiveness, 2012-2013. Centers for disease control and prevention. 2018 Sep [accessed 2022 Dec]. https://www.cdc.gov/flu/vaccines-work/2012-2013.html
   Google Scholar
• Cobey S, Gouma S, Parkhouse K, Chambers BS, Ertl HC, Schmader KE, Halpin RA, Lin X, Stockwell TB, Das SR, et al. Poor immunogenicity, not vaccine strain egg adaptation, May explain the low H3N2 influenza vaccine effectiveness in 2012–2013. Clinical Infectious Diseases. 2018 Jul 18;67(3):327–33. doi:10.1093/cid/ciy097.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Seasonal Influenza Vaccine Effectiveness, 2015-2016. Centers for disease control and prevention. 2019 Oct [accessed 2022 Dec]. https://www.cdc.gov/flu/vaccines-work/2015-2016.html
   Google Scholar
• Centers for Disease Control and Prevention. Seasonal Influenza Vaccine Effectiveness, 2016-2017. Centers for disease control and prevention. 2018 Sep [accessed 2022 Dec]. https://www.cdc.gov/flu/vaccines-work/2016-2017.html
   Google Scholar
• Lee IT, Nachbagauer R, Ensz D, Schwartz H, Carmona L, Schaefers K, Avanesov A, Stadlbauer D, Henry C, Chen R, et al. Safety and immunogenicity of a phase 1/2 randomized clinical trial of a quadrivalent, mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults: interim analysis. Nat Commun. 2023 Jun 19;14(1):3631. doi:10.1038/s41467-023-39376-7.
   PubMed Web of Science ®Google Scholar
• Soens M, Kandinov B, Ramirez-Schrempp D, Vakil J, Pucci A, Huang W, Guo J, Du E, Avanesov A, Rudden S, et al. A review of clinical safety, reactogenicity, and immunogenicity of an mRNA-based seasonal influenza vaccine (mRNA-1010) in adults. Open Forum Infect Dis. 2023;10(Supplement_2): 1639. doi: 10.1093/ofid/ofad500.1473.
   Google Scholar
• NCT05540522. A study to evaluate a modified RNA vaccine against influenza in adults 18 years of age or older. https://www.clinicaltrials.gov/study/NCT05540522
   Google Scholar
• Edwards DK, Carfi A. Messenger ribonucleic acid vaccines against infectious diseases: current concepts and future prospects. Curr Opin Immunol. 2022 Aug;77:102214. doi:10.1016/j.coi.2022.102214.
   PubMed Web of Science ®Google Scholar
• Wilson E, Goswami J, Baqui AH, Doreski PA, Perez-Marc G, Zaman K, Monroy J, Duncan CJA, Ujiie M, Rämet M, et al. Efficacy and safety of an mRNA-based RSV PreF vaccine in older adults. N Engl J Med. 2023;389(24):2233–44. doi:10.1056/NEJMoa2307079.
   PubMed Web of Science ®Google Scholar
• Weir JP, Gruber MF. An overview of the regulation of influenza vaccines in the United States. Influenza Other Respir Viruses. 2016 Sep;10(5):354–60. doi:10.1111/irv.12383.
   PubMed Web of Science ®Google Scholar
• Bartley JM, Cadar AN, Martin DE. Better, faster, stronger: mRNA vaccines show promise for influenza vaccination in older adults. Immunol Invest. 2021 Oct;50(7):810–20. doi:10.1080/08820139.2021.1909617.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. FDA briefing document: vaccines and related biological products advisory committee meeting. 2023 Jun 15. https://www.fda.gov/media/169378/download
   Google Scholar
• Neuzil KM. An mRNA influenza vaccine - could it deliver? N Engl J Med. 2023 Mar 23;388(12):1139–41. doi:10.1056/NEJMcibr2215281.
   PubMed Web of Science ®Google Scholar
• Chalkias S, Harper C, Vrbicky K, Walsh SR, Essink B, Brosz A, McGhee N, Tomassini JE, Chen X, Chang Y, et al. A bivalent omicron-containing booster vaccine against covid-19. N Engl J Med. 2022 Oct 6;387(14):1279–91. doi:10.1056/NEJMoa2208343.
   PubMed Web of Science ®Google Scholar
• Link-Gelles R, Ciesla AA, Fleming-Dutra KE, Smith ZR, Britton A, Wiegand RE, Miller JD, Accorsi EK, Schrag SJ, Verani JR, et al. Effectiveness of bivalent mRNA vaccines in preventing symptomatic SARS-CoV-2 infection — increasing community access to testing program, United States, September–November 2022. MMWR Morb Mortal Wkly Rep. 2022 Dec 2;71(48):1526–30. doi:10.15585/mmwr.mm7148e1.
   PubMed Web of Science ®Google Scholar
• Arevalo CP, Bolton MJ, Le Sage V, Ye N, Furey C, Muramatsu H, Alameh M-G, Pardi N, Drapeau EM, Parkhouse K, et al. A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes. Science. 2022 Nov 25;378(6622):899–904. doi:10.1126/science.abm0271.
   PubMed Web of Science ®Google Scholar
• Couch RB, Atmar RL, Franco LM Quarles JM, Wells J, Arden N, Niño D, Belmont JW. Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase. J Infect Dis. 2013 Mar 15;207(6):974–81. doi:10.1093/infdis/jis935.
   PubMed Web of Science ®Google Scholar
• Monto AS, Petrie JG, Cross RT, Johnson E, Liu M, Zhong W, Levine M, Katz JM, Ohmit SE. Antibody to influenza virus neuraminidase: an Independent correlate of protection. J Infect Dis. 2015 Oct 15;212(8):1191–9. doi:10.1093/infdis/jiv195.
   PubMed Web of Science ®Google Scholar
• Westgeest KB, de Graaf M, Fourment M, Bestebroer TM, van Beek R, Spronken MIJ, de Jong JC, Rimmelzwaan GF, Russell CA, Osterhaus ADME, et al. Genetic evolution of the neuraminidase of influenza a (H3N2) viruses from 1Pt 968 to 2009 and its correspondence to haemagglutinin evolution. J Gen Virol. 2012 Sep;93(9):1996–2007. doi:10.1099/vir.0.043059-0.
   PubMedGoogle Scholar
• Sandbulte MR, Westgeest KB, Gao J, Xu X, Klimov AI, Russell CA, Burke DF, Smith DJ, Fouchier RAM, Eichelberger MC, et al. Discordant antigenic drift of neuraminidase and hemagglutinin in H1N1 and H3N2 influenza viruses. Proc Natl Acad Sci USA. 2011 Dec 20;108(51):20748–53. doi:10.1073/pnas.1113801108.
   PubMed Web of Science ®Google Scholar
• Dolgin E. mRNA flu shots move into trials. Nat Rev Drug Discov. 2021 Nov;20(11):801–3. doi:10.1038/d41573-021-00176-7.
   PubMed Web of Science ®Google Scholar
• Ortiz de Lejarazu-Leonardo R, Montomoli E, Wojcik R, Christopher S, Mosnier A, Pariani E, Trilla Garcia A, Fickenscher H, Gärtner BC, Jandhyala R, et al. Estimation of reduction in influenza vaccine effectiveness due to egg-adaptation changes—systematic literature review and expert consensus. Vaccines. 2021 Oct 29;9(11):1255. doi:10.3390/vaccines9111255.
   Web of Science ®Google Scholar
• Lin Y, Wharton SA, Whittaker L, Dai M, Ermetal B, Lo J, Pontoriero A, Baumeister E, Daniels RS, McCauley JW, et al. The characteristics and antigenic properties of recently emerged subclade 3C.3a and 3C.2a human influenza A(H3N2) viruses passaged in MDCK cells. Influenza Other Respir Viruses. 2017 May;11(3):263–74. doi:10.1111/irv.12447.
   PubMed Web of Science ®Google Scholar
• Tang CY, Segovia K, McElroy JA, Li T, Guan M, Zhang X, Misra S, Hang J, Wan X-F. Cell-adapted mutations and antigenic diversity of influenza B viruses in Missouri, 2019–2020 season. Viruses. 2021 Sep 22;13(10):1896. doi:10.3390/v13101896.
   PubMed Web of Science ®Google Scholar
• Rajaram S, Suphaphiphat P, van Boxmeer J, Haag M, Leav B, Iheanacho I, Kistler K, Ortiz de Lejarazu R. Retrospective assessment of the antigenic similarity of egg-propagated and cell culture-propagated reference influenza viruses as compared with circulating viruses across influenza seasons 2002–2003 to 2017–2018. Int J Environ Res Public Health. 2020 Jul 28;17(15):5423. doi:10.3390/ijerph17155423.
   PubMed Web of Science ®Google Scholar
• Izurieta HS, Chillarige Y, Kelman J, Wei Y, Lu Y, Xu W, Lu M, Pratt D, Chu S, Wernecke M, et al. Relative effectiveness of cell-cultured and egg-based influenza vaccines among elderly persons in the United States, 2017–2018. J Infect Dis. 2019 Sep 13;220(8):1255–64. doi:10.1093/infdis/jiy716.
   PubMed Web of Science ®Google Scholar
• Izurieta HS, Chillarige Y, Kelman J, Wei Y, Lu Y, Xu W, Lu M, Pratt D, Wernecke M, MaCurdy T, et al. Relative effectiveness of influenza vaccines among the United States elderly, 2018–2019. J Infect Dis. 2020 Jun 29;222(2):278–87. doi:10.1093/infdis/jiaa080.
   PubMed Web of Science ®Google Scholar
• Izurieta HS, Lu M, Kelman J, Lu Y, Lindaas A, Loc J, Pratt D, Wei Y, Chillarige Y, Wernecke M, et al. Comparative effectiveness of influenza vaccines among US medicare beneficiaries ages 65 years and older during the 2019–2020 season. Clinical Infectious Diseases. 2021 Dec 6;73(11):4251–9. doi:10.1093/cid/ciaa1727.
   Web of Science ®Google Scholar
• Wang W, Alvarado-Facundo E, Vassell R, Collins L, Colombo RE, Ganesan A, Geaney C, Hrncir D, Lalani T, Markelz AE, et al. Comparison of A(H3N2) neutralizing antibody responses elicited by 2018–2019 season quadrivalent influenza vaccines derived from eggs, cells, and recombinant hemagglutinin. Clinical Infectious Diseases. 2021 Dec 6;73(11):4312–20. doi:10.1093/cid/ciaa1352.
   Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. How influenza (Flu) vaccines are made. [accessed 2022]. https://www.cdc.gov/flu/prevent/how-fluvaccine-made.htm
   Google Scholar
• Dunkle LM, Izikson R, Patriarca P, Goldenthal KL, Muse D, Callahan J, Cox MMJ. Efficacy of recombinant influenza vaccine in adults 50 years of age or older. N Engl J Med. 2017 Jun 22;376(25):2427–36. doi:10.1056/NEJMoa1608862.
   PubMed Web of Science ®Google Scholar
• Zimmerman RK, Dauer K, Clarke L, Nowalk MP, Raviotta JM, Balasubramani GK. Vaccine effectiveness of recombinant and standard dose influenza vaccines against outpatient illness during 2018-2019 and 2019-2020 calculated using a retrospective test-negative design. Hum Vaccin Immunother. 2023 Dec 31;19(1):2177461. doi:10.1080/21645515.2023.2177461.
   PubMed Web of Science ®Google Scholar
• Hsiao A, Yee A, Fireman B, Hansen JR, Lewis N, Klein NP. Effectiveness of recombinant influenza vaccine vs. standard dose inactivated influenza vaccines against hospitalized influenza-related outcomes in adults: a cluster randomized trial. Open Forum Infect Dis. Dec 2022;9(Suppl 2): 2322. doi:10.1093/ofid/ofac492.153.
   Google Scholar
• Poulos C, Leach CA, Kent C, Rudin D, Buck P, Ghaswalla P. PCR47 consumer preferences for attributes of influenza vaccines in the United States: results from a discrete-choice experiment study. Value Health. 2023;26(12):S457. doi:10.1016/j.jval.2023.09.2486.
   Web of Science ®Google Scholar